- Effects of long-term Irbesartan in reducing portal pressure in cirrhotic patients: comparison with propranolol in a randomised controlled studyWilma Debernardi Venon
Department of Gastroenterology, Ospedale Molinette, S Giovanni Battista Hospital, c so Bramante 88, 10126, Turin, Italy
J Hepatol 38:455-60. 2003..We tested the efficacy of Irbesartan (Irb) vs. Propranolol (Pro) in reducing portal pressure and evaluated its systemic haemodynamic effects...
- Prospective randomized trial: endoscopic follow up 3 vs 6 months after esophageal variceal eradication by band ligation in cirrhosisWilma Debernardi Venon
Gastro Hepatology Unit, San Giovanni Battista Hospital, University of Turin, Italy Electronic address
Eur J Intern Med 25:674-9. 2014..The aim of this prospective randomized trial was to assess the most effective timing of endoscopic monitoring after variceal eradication and its impact on the patient's outcome and on the costs...
- AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markersWilma Debernardi-Venon
Division of Gastroenterology and Hepatology, S Giovanni Battista Hospital, Turin, Italy
J Hepatol 46:1026-33. 2007..To examine the long-term effects of Candesartan cilexetil, an angiotensin type 1 (AT1) receptor blocker, on portal-systemic haemodynamics and on liver fibrosis...